InterPharma loses bid to invalidate Pfizer’s Precedex patent
Campbell Thompson 2019-06-24 11:54 am By Miklos Bolza | Sydney
Please login to bookmark Close

Global pharmaceutical giant Pfizer has successfully defended the patent for its sedative drug Precedex against a validity challenge, a big win for the drug maker after a US court found last year that its patents for a ready-to-use version of the drug were invalid for obviousness.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au